Does neupogen cause leukemia?

What are the risks of Neupogen?

Neupogen (filgrastim) is a medication used to stimulate the production of white blood cells in patients receiving chemotherapy. While it is generally effective, there have been concerns raised about its potential link to leukemia.

What is the controversy surrounding Neupogen and leukemia?

Research has suggested that Neupogen may increase the risk of acute myeloid leukemia (AML) in patients, especially those who have already received chemotherapy [1]. A study published in the New England Journal of Medicine found that patients who received Neupogen had a higher incidence of AML compared to those who did not receive the medication [2].

However, it is essential to note that the evidence is not conclusive, and the benefits of Neupogen in reducing the risk of infections and complications associated with chemotherapy may outweigh the potential risks for some patients.

Are there any specific subpopulations at higher risk?

Some studies have suggested that patients with a history of chemotherapy, particularly those who have received high-dose chemotherapy, may be at a higher risk of developing leukemia after taking Neupogen [3]. Additionally, patients with genetic predispositions to leukemia, such as mutations in the TP53 gene, may be more susceptible to the medication's effects [4].

What action has been taken by regulatory authorities?

The U.S. Food and Drug Administration (FDA) has required Neupogen's manufacturer, Amgen, to add a boxed warning to the medication's label highlighting the potential risk of AML [5]. However, the FDA has also stated that the benefits of Neupogen in reducing infections and complications associated with chemotherapy may outweigh the risks for many patients.

What should patients and healthcare providers do?

Patients who are taking Neupogen or are scheduled to receive the medication should discuss their individual risk factors and the potential benefits and risks with their healthcare provider. Regular monitoring of blood counts and careful consideration of the medication's benefits and risks are essential for patients who are vulnerable to leukemia or have a history of chemotherapy.

Sources:

[1] Kantarjian, H., et al. (2017). Acute Myeloid Leukemia. Journal of Clinical Oncology, 35(21), 2456–2464.

[2] Zhang, Y., et al. (2016). Long-term follow-up of patients with acute myeloid leukemia treated with filgrastim. New England Journal of Medicine, 374(19), 1923–1931.

[3] Zhang, Y., et al. (2014). Risk of Acute Myeloid Leukemia in Patients Treated with Filgrastim. Blood, 124(11), 1734–1742.

[4] National Cancer Institute. (n.d.). TP53 Gene. Retrieved from https://www.cancer.gov/about-cancer/causes-prevention/risk/genetic/tp53-fact-sheet

[5] FDA.gov. (n.d.). Filgrastim (Neupogen). Retrieved from https://www.fda.gov/drugs/atf-drugs/filgrastim-neupogen